Smith Salley Wealth Management Has $20.61 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Smith Salley Wealth Management reduced its stake in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 24.9% during the 1st quarter, reports. The firm owned 156,227 shares of the company’s stock after selling 51,748 shares during the period. Merck & Co., Inc. makes up 1.6% of Smith Salley Wealth Management’s investment portfolio, making the stock its 19th biggest position. Smith Salley Wealth Management’s holdings in Merck & Co., Inc. were worth $20,614,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of MRK. Vermillion & White Wealth Management Group LLC bought a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $27,000. Bare Financial Services Inc acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at about $28,000. Burkett Financial Services LLC bought a new position in Merck & Co., Inc. in the fourth quarter valued at about $28,000. Rakuten Securities Inc. acquired a new position in Merck & Co., Inc. during the fourth quarter worth about $30,000. Finally, RIA Advisory Group LLC bought a new position in shares of Merck & Co., Inc. in the fourth quarter worth about $30,000. Institutional investors own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on MRK shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price target on shares of Merck & Co., Inc. in a report on Tuesday, June 18th. Berenberg Bank boosted their target price on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Truist Financial increased their price target on Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Argus upgraded Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, June 5th. Finally, Wells Fargo & Company upped their target price on Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.00.

View Our Latest Stock Report on MRK

Merck & Co., Inc. Trading Up 0.3 %

Shares of NYSE MRK traded up $0.42 during trading on Wednesday, reaching $126.46. The company had a trading volume of 202,688 shares, compared to its average volume of 8,392,787. The stock has a market cap of $320.30 billion, a P/E ratio of 140.09, a PEG ratio of 2.43 and a beta of 0.38. The company’s fifty day moving average price is $128.99 and its 200-day moving average price is $125.39. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.77. Merck & Co., Inc. has a 12 month low of $99.14 and a 12 month high of $134.63.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its quarterly earnings data on Thursday, April 25th. The company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.21 billion. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.40 earnings per share. As a group, research analysts expect that Merck & Co., Inc. will post 8.62 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, July 8th. Stockholders of record on Monday, June 17th were paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.44%. The ex-dividend date was Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio is currently 342.22%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Want to see what other hedge funds are holding MRK? Visit to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with's FREE daily email newsletter.